Corvus Pharmaceuticals, Inc. (CRVS) — SEC Filings
Corvus Pharmaceuticals, Inc. (CRVS) — 35 SEC filings. Latest: 8-K (Nov 4, 2025). Includes 19 8-K, 6 10-Q, 3 SC 13G/A.
View Corvus Pharmaceuticals, Inc. on SEC EDGAR
Overview
Corvus Pharmaceuticals, Inc. (CRVS) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 4, 2025: Corvus Pharmaceuticals, Inc. reported a net loss of $10.157 million for the three months ended September 30, 2025, a significant improvement from the $40.217 million net loss in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $2.962 million, substantially lowe
Sentiment Summary
Across 35 filings, the sentiment breakdown is: 1 bearish, 33 neutral, 1 mixed. The dominant filing sentiment for Corvus Pharmaceuticals, Inc. is neutral.
Filing Type Overview
Corvus Pharmaceuticals, Inc. (CRVS) has filed 19 8-K, 6 10-Q, 1 DEFA14A, 2 10-K, 3 SC 13G/A, 2 SC 13G, 1 SC 13D/A, 1 DEF 14A with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (35)
Risk Profile
Risk Assessment: Of CRVS's 27 recent filings, 2 were flagged as high-risk, 9 as medium-risk, and 16 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Net Income | -$2,962,000 |
| EPS | -$0.04 |
| Cash Position | $2,867,000 |
| Total Assets | $80,474,000 |
| Total Debt | $8,706,000 |
Key Executives
- Dr. Richard A. Miller
- Ms. Jennifer L. D. Allison
- Mr. David M. E. Smith
Industry Context
Corvus Pharmaceuticals operates in the highly competitive biotechnology sector, focusing on the development of novel therapeutics for cancer and infectious diseases. The industry is characterized by long development cycles, high R&D costs, significant regulatory hurdles, and the need for substantial capital investment. Success often hinges on clinical trial outcomes and the ability to secure ongoing funding.
Top Tags
financials (6) · financial-reporting (4) · 8-k (4) · 10-Q (4) · Biotechnology (3) · corporate-governance (3) · 8-K (3) · sec-filing (3) · filing (3) · Clinical Stage (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss (Q3 2025) | $10.157M | Significant improvement from $40.217M in Q3 2024 |
| Net Loss (9M 2025) | $2.962M | Substantially lower than $50.180M in 9M 2024 |
| Change in fair value of warrant liability (9M 2025) | $27.141M | Positive change, contributing to reduced net loss |
| Research and development expenses (9M 2025) | $23.780M | Increased from $13.411M in 9M 2024, reflecting pipeline investment |
| Cash and cash equivalents (Sep 30, 2025) | $2.867M | Decreased from $8.740M at Dec 31, 2024 |
| Marketable securities (Sep 30, 2025) | $62.822M | Increased from $43.224M at Dec 31, 2024 |
| Proceeds from common stock warrants exercise (9M 2025) | $35.745M | Key financing activity |
| Accumulated deficit (Sep 30, 2025) | $400.0M | Indicates significant historical losses |
| Common shares outstanding (Nov 4, 2025) | 74,681,872 | Increased from 67,899,779 at Dec 31, 2024 |
| Total cash, cash equivalents and marketable securities (Sep 30, 2025) | $65.7M | Deemed insufficient for 12 months of operations |
| Revenue | $0 | No revenue for Q2 2025 or Q2 2024, highlighting clinical-stage status. |
| Net Loss (Q2 2025) | -$7.4M | Improved from -$10.1M in Q2 2024, primarily due to reduced R&D expenses. |
| Net Loss (YTD Q2 2025) | -$15.2M | Improved from -$20.3M in YTD Q2 2024, reflecting cost management. |
| R&D Expenses (Q2 2025) | $5.5M | Decreased from $7.8M in Q2 2024, indicating reduced clinical trial activity. |
| G&A Expenses (Q2 2025) | $2.0M | Slightly decreased from $2.3M in Q2 2024, showing some operational cost control. |
Frequently Asked Questions
What are the latest SEC filings for Corvus Pharmaceuticals, Inc. (CRVS)?
Corvus Pharmaceuticals, Inc. has 35 recent SEC filings from Jan 2024 to Nov 2025, including 19 8-K, 6 10-Q, 3 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of CRVS filings?
Across 35 filings, the sentiment breakdown is: 1 bearish, 33 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Corvus Pharmaceuticals, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Corvus Pharmaceuticals, Inc. (CRVS) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Corvus Pharmaceuticals, Inc.?
Key financial highlights from Corvus Pharmaceuticals, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for CRVS?
The investment thesis for CRVS includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Corvus Pharmaceuticals, Inc.?
Key executives identified across Corvus Pharmaceuticals, Inc.'s filings include Dr. Richard A. Miller, Ms. Jennifer L. D. Allison, Mr. David M. E. Smith.
What are the main risk factors for Corvus Pharmaceuticals, Inc. stock?
Of CRVS's 27 assessed filings, 2 were flagged high-risk, 9 medium-risk, and 16 low-risk.
What are recent predictions and forward guidance from Corvus Pharmaceuticals, Inc.?
Forward guidance and predictions for Corvus Pharmaceuticals, Inc. are extracted from SEC filings as they are enriched.